TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04398550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Carbohydrate Diet
Description: Diet restricts all but simple carbohydrates and allows for inclusion of fresh fruits, vegetables, unprocessed meats, and homemade lactose-free cheese and yogurt.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Diet rich in whole vegetables, fruit, plant-based protein, and olive oil, with moderate amounts of seafood and dairy, and limited in sugar-sweetened goods, red meat, and nutrients like heme and sodium.
Study: NCT00416455

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG PET/CT
Study: NCT02601287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Botulinum Toxin Type A into detrusor muscle on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Botulinum Toxin Type A into detrusor muscle on Day 1
Study: NCT03049839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention_ I
Description: One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention_ C
Description: One year, Intervention program at Community level. People with a FINDRISC less than 12 points
Study: NCT00829595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
Description: 0.5mL intramuscular, one time

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
Description: 0.5mL intramuscular, one time

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
Description: 0.5mL intramuscular, one time
Study: NCT00135694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcineurin inhibitor-based immunosuppression
Description: May be cyclosporine, mycophenolate mofetil, or tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcineurin inhibitor-based immunosuppression
Description: May be cyclosporine, mycophenolate mofetil, or tacrolimus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver transplant
Description: Occurs at study entry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver transplant
Description: Occurs at study entry

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: 3-month course of corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: 3-month course of corticosteroids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunosuppression withdrawal
Description: One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
Study: NCT02960802

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kidney transplantation
Study: NCT03528811

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Five points test of Tongji university
Description: In each group, we will evaluate the microcirculation of diabetic foot using the newly-established Five points test of Tongji university before or after the operation, and then compare the temperature of the five points with the other data.
Study: NCT03310749

Intervention type: DRUG
Group type: OTHER
Intervention: Gemigliptin
Description: A 7-day treatment period with gemigliptin 50 mg q.d., followed by a 5-day washout period; a 7 day treatment period with metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day

Intervention type: DRUG
Group type: OTHER
Intervention: Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
Description: A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day

Intervention type: DRUG
Group type: OTHER
Intervention: Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
Description: A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day
Study: NCT03984682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Crisis Plan
Description: A Joint Crisis Plan will be drafted with the patient and a nurse
Study: NCT03720158

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 Group
Description: Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo or Control Group
Description: Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
Study: NCT03900182

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: The Hyperbaric Oxygen Therapy (HBOT) patients were placed in a chamber that was pressurized with air to 2.5 ATA during 15 min and were supplied 100% oxygen for 25 mins, followed by a 5-min air break. This cycle was repeated once and followed by 100% oxygen for 10 min, after which time the chamber was depressurized to 1 ATA over 15 min with 100% oxygen for a total treatment time of 100 min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: The Hyperbaric Oxygen Therapy (HBOT) patients were placed in a chamber that was pressurized with air to 2.5 ATA during 15 min and were supplied 100% oxygen for 25 mins, followed by a 5-min air break. This cycle was repeated once and followed by 100% oxygen for 10 min, after which time the chamber was depressurized to 1 ATA over 15 min with 100% oxygen for a total treatment time of 100 min.
Study: NCT02127580

Intervention type: PROCEDURE
Intervention: BAV

Intervention type: PROCEDURE
Intervention: without BAV
Study: NCT03341091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai-chi group
Description: The Tai-chi group received a 16-week 10-step simplified Tai-chi training programme in which additional measures were implemented to enhance participants' engagement.
Study: NCT00416455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG PET/CT
Study: NCT01868126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 ophthalmic solution
Study: NCT02871388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONECT
Description: 1 monthly in person + 1 monthly telephone + 4 monthly email contact for behavior modification. Focus on motivation, self efficacy and information provision.
Study: NCT02295995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise as an Adjuvant Therapy for Veterans with PTSD
Description: Methods: Approximately 50 Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care wait-list control. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
Study: NCT04422028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel 0.075 MG
Description: Test Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desogestrel 0.075 MG
Description: Reference Product
Study: NCT03762382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV/LNG IVR
Description: TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV IVR
Description: TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.
Study: NCT00416455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FDG PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferumoxtran-10
Description: Undergo femoxtran-10 MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo femoxtran-10 MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagnostic lymphadenectomy
Description: Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
Study: NCT01868126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost ophthalmic solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00416455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node biopsy
Description: Undergo pelvic and abdominal lymph node biopsy
Study: NCT02280317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL201
Description: VAL201-001 Sub-cutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL201
Description: VAL201-001 Sub-cutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL201
Description: VAL201-001 Sub-cutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL201
Description: VAL201-001 Sub-cutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL201
Description: VAL201-001 Sub-cutaneous injection.
Study: NCT04192552

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAUSE Perioperative DOAC Management
Description: Apixaban \& Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl \<50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAUSE Perioperative DOAC Management
Description: Apixaban \& Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl \<50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAUSE Perioperative DOAC Management
Description: Apixaban \& Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl \<50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ASRA Perioperative DOAC Management
Description: Apixaban \& Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl \>80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~\*Low-dose heparin bridging can be used if at high A-TE risk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ASRA Perioperative DOAC Management
Description: Apixaban \& Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl \>80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~\*Low-dose heparin bridging can be used if at high A-TE risk
Study: NCT03762382

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IVR
Description: Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.
Study: NCT03215329

Intervention type: PROCEDURE
Intervention: abdominal or vascular surgery
Description: Intermediate or high risk abdominal or vascular surgery
Study: NCT04192552

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ASRA Perioperative DOAC Management
Description: Apixaban \& Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl \>80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~\*Low-dose heparin bridging can be used if at high A-TE risk
Study: NCT01636076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QMF149
Description: delivered via Concept1 device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: delivered via Accuhaler®
Study: NCT05058066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm abutment
Description: The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baha® BIA300 Implant (diameter 4.5mm; length 4mm) with 6mm abutment
Description: The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment. In addition to the difference in abutment shape and the wider diameter, the test implant incorporates small-sized threads at the implant neck and the moderately rough TiOblast™ (Dentsply, Mölndal, Sweden) surface on the intraosseous part of the implant6-8.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baha® BIA300 Implant (diameter 4.5mm; length 4mm) with 6mm abutment
Description: The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment. In addition to the difference in abutment shape and the wider diameter, the test implant incorporates small-sized threads at the implant neck and the moderately rough TiOblast™ (Dentsply, Mölndal, Sweden) surface on the intraosseous part of the implant6-8.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early loading
Description: Loading the implant at 3 weeks after implantation (instead of 6 weeks after implantation)
Study: NCT02936206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 14 days of treatment with tamoxifen 20mg orally each day
Study: NCT02661789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin 3.6 mg implant
Description: Pharmacologically induced biphasic sex-steroid hormone fluctuation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of saline
Study: NCT03581032

Intervention type: DEVICE
Intervention: Active reprogam
Description: Reprogram Changes in AV/PV delays

Intervention type: DEVICE
Intervention: Active reprogam
Description: Reprogram Changes in AV/PV delays
Study: NCT00986817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
Study: NCT02369757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigator intervention
Description: peers sharing common characteristics with the target population whose mission is to accompany towards OCCS
Study: NCT02409017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin drip

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin drip
Study: NCT03648047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital kinematic biofeedback device
Description: The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Patients will receive conventional face-to-face sessions by a Physical Therapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional face-to-face rehabilitation sessions
Description: Patients will receive face-to-face sessions in addition to sessions performed with the Digital Rehabilitation Device
Study: NCT01475812

Intervention type: OTHER
Intervention: Hyperinflation and ADL
Description: Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
Study: NCT02874222

Intervention type: OTHER
Intervention: surveys completed by subject
Description: Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.

Intervention type: OTHER
Intervention: surveys completed by subject
Description: Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.

Intervention type: OTHER
Intervention: surveys completed by subject
Description: Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
Study: NCT00265876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: Taken daily every 4 weeks
Study: NCT03422666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Teduglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04471324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS cryo probe
Description: patients receive a transbronchial cryo biopsy with the EBUS cryo probe from ERBE and an ultra thin bronchoskope
Study: NCT03063268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trust-Enhanced Messaging on E-Consent
Description: Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive features on E-Consent
Description: Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive features on E-Consent
Description: Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard E-Consent
Description: Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard E-Consent
Description: Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard E-Consent
Description: Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
Study: NCT04534881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 200 MG
Description: Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
Study: NCT01008449

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical staples
Description: Surgical staples will be used once for wound closure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable Surgical Suture
Description: Absorbable surgical suture will be used for subcuticular closure at the time of wound closure for cesarean delivery.
Study: NCT01506011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Besylate/Benazepril HCl
Description: Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate/Benazepril HCl
Description: Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
Study: NCT04481061

Intervention type: GENETIC
Group type: OTHER
Intervention: Electronic Decision Tool
Description: Adolescents and a parent, if applicable, will use an electronic decision tool to make categorical choices of types of diseases (treatable, preventable, adult-onset, and carrier status) they want to learn about the adolescent. Granular choices can be made within each category.